Business
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can be used anywhere on the body for any duration and is not a steroidAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in the United States. ZORYVE cream 0.05% is a once-daily, steroid-free topical treatment that provides long-term disease control with no limitation on duration of use. In clinical trials, ZORYVE cream 0.05% had positive results across all efficacy endpoints, including significant clearance of atopic dermatitis signs and symptoms and meaningful improvement in itch. This launch expands the ZORYVE portfolio to a younger pediatric population, making ZORYVE cream available for children with mild to moderate atopic dermatitis as young as 2 years old. “Atopic dermatitis is one of the most common chronic skin conditions in young children, yet safe and effective long-term treatment options have been limited, especially for children ages 2 to 5,” said Todd Edwards, chief commercial officer at Arcutis. “With ZORYVE cream 0.05%, families have a once-daily, steroid-free, and well-tolerated treatment that targets the underlying inflammation of atopic dermatitis. ZORYVE provides a foundation for ongoing control, and can be used for any duration, anywhere on the body, with no restrictions on body surface area. We are excited to make this important treatment widely available to help improve outcomes for children and their families.” ZORYVE cream 0.05% will be available in pharmacies this week. The product is being reviewed by commercial pharmacy benefit managers and other plans to enable similar coverage as the entire ZORYVE portfolio. “In my practice, I’ve seen firsthand how challenging atopic dermatitis can be for young children who deal with discomfort from the itch and rash, which can disrupt daily ac...